

Index to Volume Thirty

Index of Issues: January, 1-98; February, 99-186; March, 187-272; April, 273-368; May, 369-476; June, 477-532; July, 533-592; August, 593-670; September, 671-735; October, 737-802; November, 803-870; December, 871-934.

INDEX OF AUTHORS

- A**
- Abel M, 362
 Abraham CD, 549
 Abrahamowicz M, 581
 ACSAG Investigators, 6
 Adams AL, 764
 Adams EJ, 379
 Adler B, 874
 Ahlman K, 114
 Ahmed HJ, 114
 Alarcon J, 273
 Alary M, 46
 Alcalá B, 395
 Alexander L, 193
 Almirall R, 788
 Alter MJ, 340
 Amestoy GM, 593
 Amida X, 664
 Anderson JE, 719
 Anderson K, 91
 Anderson LA, 30
 Anoma CK, 284
 Antolin I, 395
 Antonio MAD, 568
 Apter D, 120
 Aral SO, 39, 71, 221, 419, 750
 Armenian HK, 199
 Aronson N, 713
 Arreaza L, 395
 Ashley-Morrow R, 310
 Awasana AA, 483
 Ayoub M, 731
- B**
- Bachmann LH, 20, 335
 Bäckman A, 205
 Baker MA, 650
 Bala M, 523
 Bandama C, 284
 Barcellos NT, 166
 Barivelo T, 664
 Bass DC, 71
 Becker TM, 764
 Begley E, 211
 Behets F, 262, 664
 Beltrami JF, 526
 Berman SM, 49, 472, 528
 Bernstein DI, 774
 Bernstein KT, 199
 Biro FM, 752
 Blair R, 866
 Blandford JM, 502
 Blazes DL, 713
 Blejan C, 866
 Boehner CW, 774
 Boelle P-Y, 6
 Boerma JT, 779
 Bolan G, 49
 Borrell N, 395
 Bosch FX, 788
 Boselli F, 707
 Boskey ER, 107
 Bowen AM, 571
 Branovskaja M, 680
 Brennan CH, 340
 Brewer T, 914
 Brodine S, 545, 713
- Brown C, 575
 Brown DR, 246
 Brown P, 689
 Brunham RC, 297
 Buchanan K, 273
 Bull SS, 15
 Burkhardt G, 664
 Burk RD, 575
 Burman WJ, 399
 Butler N, 609
- C**
- Cacho J, 395
 Callahan DB, 340, 645
 Calvet H, 49
 Campbell P, 33
 Campos PE, 273
 Carrel D, 174
 Carreño F, 280
 Carrillo C, 273
 Carvalho SE, 694
 Casey S, 874
 Casper C, 713
 Castellanos S, 195
 Castle PE, 575
 Catala I, 788
 Celentano DD, 185
 Chagas C, 694
 Chaowanachan T, 320
 Chaw JK, 509, 661
 Chemeris G, 680
 Chen R, 600
 Chen S, 362, 609
 Chernesky M, 345, 880, 905
 Cherpes TL, 405
 Chesson HW, 419
 Chilongozi D, 516
 Chiossi G, 707
 Choi K-H, 91
 Chong S, 345
 Chrisnadarmani VAMA, 671
 Christensen NO, 262
 Chu B-C, 614
 Ciaffi L, 671
 Ciesielski CA, 650
 Cintorino M, 680
 Claeys P, 137
 Clark R, 839
 Cocuroccia B, 157
 Cohen DA, 844
 Cohen MS, 516
 Cohn DL, 399
 Conde-Glez CJ, 266, 549
 Cone RA, 107
 Connell FA, 99
 Connolly C, 1, 241
 Coplan PM, 246
 Corey L, 174, 425, 713
 Cosgrove Sweeney YT, 568
 Costa MC, 581
 Costa PL, 694
 Courtois B, 273
 Craig T, 83
 Cranston B, 575
 Crosby RA, 57, 211, 634, 909
 Crum NF, 713
 Cruz-Valdez A, 549
- Cuesta M, 280
- D**
- Dallabetta G, 664
 Dan M, 794, 835
 Davies SC, 671
 Dee TS, 419
 de las Cuevas C, 395
 Demba E, 483
 De P, 497
 de Sanjose S, 788
 Desmond R, 335
 Detels R, 327, 411, 803
 De Vuyst H, 137
 Diamond C, 425
 Diao J, 600
 Diaz M, 788
 DiCello AC, 246
 Dicker LW, 472
 Dickson N, 818
 DiClemente RJ, 57, 211, 449, 634, 909
 Dilley J, 331, 874, 919
 Dillon J-AR, 443
 Donegan E, 905
 Dorst D, 75
 Douglas JM, 562
 Douglas JM Jr, 15
 Douglas W, 411, 685
 Downs J, 71
 D'Souza G, 872
 Dutro SM, 756
- E**
- Eckert LO, 357
 Edmunds WJ, 379
 Egger M, 129
 Ellen JM, 234, 533, 825
 Engelberg R, 174
 Ennis DM, 512
 Erokhina O, 680
 Escoffery C, 575
 Espinosa E, 292
 Esquivel CA, 195
 Essex M, 187
 Essien EJ, 110
 Esteban JI, 470
 Esteban R, 470
 Ethier K, 809
 Ettiegne-Traore V, 284
 Ezcarzaga MLB, 195
- F**
- Fairchok MP, 901
 Fairley CK, 886
 Falk L, 205
 Farley TA, 75, 654, 839, 844
 Fawzi WW, 187
 Feijó G, 694
 Feldblum PJ, 440
 Fenton J, 33
 Fernández-Esquer ME, 110
 Fernandez I, 809
 Fichtenberg CM, 825
 Fife KH, 246
 Flaks RC, 399
 Font R, 788
- Fortenberry JD, 49
 Foxman B, 216, 750
 Fox TL, 124
 Franco E, 581
 Fredlund H, 205
 French PP, 433
 Friedman H, 306, 531
 Fuchs FD, 166
 Fuchs SC, 166
 Funkhouser E, 689
 Furuya R, 629
- G**
- Gala P, 335
 Gallinelli A, 707
 García MJ, 280
 Garcia PJ, 379
 Garin CA, 756
 Garland S, 362, 886
 Garnett GP, 149, 379
 Gaydos CA, 64, 306, 539, 769
 Gaydos JC, 539, 769
 Geisler WM, 160
 Ghys PD, 284
 Gift TL, 502
 Gilbert BC, 719
 Gilbert LK, 193
 Gillespie B, 216
 Gilroy C, 129
 Ginocchio RHS, 99
 Girasek DC, 531
 Girolomoni G, 157
 Gisselquist D, 183
 Gittelsohn J, 149
 Glezerman M, 835
 Gmach RD, 440
 Golden MR, 490, 742
 Goldie SJ, 369
 Gollub EL, 433
 Gómez CA, 91
 Gooding E, 483
 Goossens H, 25
 Goossens W, 25
 Gotuzzo E, 273
 Gourley PJ, 399
 Greenland S, 411
 Gregorich SE, 91
 Gregson S, 779
 Grenfell BT, 388
 Grewal N III, 530
 Grice A, 362
 Grinstead O, 91
 Grosshans JF, 193
 Grujnberg A, 680
 Grujnberga V, 680
 Guan J, 803
 Guardia J, 470
 Gubinelli E, 157
 Guerino C, 114
 Gunnarsson E, 114
 Gunn RA, 340, 645
 Gutierrez AA, 195
 Gutierrez L, 273
 Guzmán D, 10

- H**
 Haikala O, 737
 Hale S, 901
 Hammer GP, 919
 Hanchard B, 575
 Handsfield HH, 49, 490, 742
 Hardick J, 64
 Hatzell T, 440
 Hawes SE, 357
 Hayes P, 886
 Hebb JK, 756
 Heckman TG, 134
 Hees PS, 107
 Hernández-Castellanos A, 266
 Hernández-Márquez C, 549
 Hernandez MT, 661
 Herrera L, 593
 Herrero R, 593, 788
 Hillier SL, 71, 257, 273, 405, 568
 Hirose T, 629
 Hobbs MM, 516
 Hoffman IF, 516
 Hogben M, 490, 742
 Holmes KK, 273, 379, 490, 742
 Homan RK, 440
 Hook EW III, 20, 335, 369, 512, 850
 Hoover DR, 433
 Horner P, 129
 Hotta H, 629
 Howard M, 880
 Howell MR, 539, 769
 Howe SR, 774
 Hoxworth T, 83
 Hsieh Y-H, 64, 769
 Hughes J, 273, 756
 Hu L, 803
 Hultunen-Back E, 737
 Humblet O, 818
 Hussain A, 588
 Hutapea N, 178
 Hutchinson ML, 575
- I**
 Ieven M, 25
 Irwin K, 30, 866
 Ivanchenko O, 680
 Iwasawa A, 629
- J**
 Jacobson LP, 199
 Jacobs RJ, 859
 Jamison D, 327
 Jang D, 345, 880
 Jansen KU, 246
 Jayaraman GC, 315
 Jeansson S, 588
 Jeeyapant S, 320
 Jenkins FJ, 199
 Jennings JM, 234
 Johansson B, 680
 Johnson G, 654, 844
 Johnson S, 83
 Johnson SM, 533
 Jolley L, 193
 Jones M, 335, 850
 Jónsdóttir K, 249
 Jordan N, 723
 Juárez-Figueroa L, 266
 Judson FN, 562
 Junquera ML, 292
 Jurstrand M, 205
- Juschenko A**, 680
- K**
 Kahn RH, 654, 700, 844
 Kaldor J, 362
 Kapiga SH, 187
 Karim SSA, 149
 Karwalajtys T, 880
 Kaun K, 362
 Kautainen H, 737
 Kaydos-Daniels SC, 516
 Kazembe PN, 516
 Keel KB, 571
 Kellogg TA, 331, 919
 Kenny GE, 756
 Kent CK, 49, 331, 368, 813
 Kerani RP, 742
 Kilmarx PH, 320
 Kilpikari R, 120
 Kim AA, 813
 Kip E, 516
 Kissinger P, 49, 75, 214, 731, 839
 Kiwelu IE, 187
 Klausner JD, 331, 368, 509, 609, 661, 813, 874, 919
 Kleter B, 137
 Kljukina L, 680
 Kobayashi I, 629
 Koenig L, 809
 Kohl K, 650
 Koroku M, 629
 Koumans EH, 700
 Kozachenko V, 680
 Krantz E, 174, 310
 Kraut-Becher JR, 221
 Kristjánsson M, 249
 Krohn MA, 405
 Krunfly C, 593
 Kruse N, 664
 Kumamoto Y, 629
 Kumari S, 523
 Kumwenda N, 185
 Kunishima Y, 629
 Kus J, 64
- L**
 Lackey PC, 512
 Laga M, 284
 Lagergård T, 114
 Lammens C, 25
 Land DJ, 348
 Lang D, 57
 Lantero MI, 10
 Lapidus JA, 764
 Latka M, 433
 Lau A, 896
 Lau JTF, 600, 620, 827
 Lazcano-Ponce E, 549
 Lazzarotto T, 157
 Lee JH, 872
 Lee JK, 234
 Lee M, 803
 Lehman JS, 764
 Le Pont F, 6
 Leutscher PDC, 262
 Levine D, 634
 Levine WC, 472
 Liang G, 803
 Li H, 443
 Li L, 803
 Limones DEC, 195
 Lindberg M, 205
- Lind I**, 178
 Lipova E, 680
 Lister NA, 886
 Liu H, 327
 Li X, 327
 Llanes R, 10, 443
 Llop A, 10, 443
 Lloveras B, 788
 Lobo TT, 694
 Loeb L, 874
 Lolis S, 844
 Londner MS, 143
 Loria D, 593
 Louie B, 331, 919
 Loveless MO, 764
 Lowndes CM, 46
 Lumpkins J, 335
 Lurie MN, 149
 Lyons EE, 30
- M**
 Macaluso M, 20
 MacKellar D, 425
 MacKinnon S, 880
 Ma E, 327
 Magid DJ, 30
 Magnus M, 75, 731, 839
 Maher JE, 75, 83
 Mahony J, 345
 Majkowski JM, 854
 Manongi R, 187
 Margolis HS, 340
 Marina RB, 226
 Markowitz LE, 49, 320, 650, 700
 Marrazzo JM, 99, 890
 Martell M, 470
 Martin DH, 49, 844
 Martínez I, 10
 Martin I, 896
 Martinko T, 901
 Martinson F, 516
 Masenga EJ, 187
 Mastro TD, 320
 Matos E, 593
 Maupin RT, 728
 Maurice CE, 284
 Mayaud P, 483
 Mayberry R, 723
 Mbizvo E, 588
 Mbwana J, 114
 McClure M, 129
 McFarland W, 331, 609, 919
 McFarlane M, 15
 McGee ZA, 530
 McKee KT Jr, 539, 769
 McLean CA, 650
 Medland NA, 886
 Medrano JC, 195
 Meheus A, 25
 Mehta SD, 143
 Meijer CJLM, 593, 788
 Merchant J, 689
 Mertz GJ, 801
 Mestad RE, 728
 Mettley A, 909
 Meyerhoff AS, 859
 Meyers M, 134
 Meyerson BE, 614
 Meyn LA, 257, 405
 Mhalu F, 114
 Michaud JM, 533
 Migliani R, 262
- Miller JM Jr**, 728
 Miller WC, 516
 Mills J, 232
 Mills L, 752, 854
 Mindel A, 232
 Minnis AM, 556
 Minor P, 723
 Mkaya-Mwamburi D, 149
 Modesitt SK, 764
 Moench TR, 107
 Moncada J, 575, 905
 Monroe KW, 850
 Moodley P, 1, 241
 Moran JS, 528
 Moreno J, 593
 Morison L, 483
 Moseley KE, 654
 Mosure DJ, 472
 Msowoya E, 516
 Msuya SE, 588
 Muchiri L, 137
 Mugabo P, 609
 Mulder PGH, 639
 Muñoz N, 593, 788
 Murillo P, 470
 Murray PJ, 340
 Myers L, 75, 839
- N**
 National Gonococcal Surveillance Program Members, 896
 National Institute of Mental Health Collaborative HIV Prevention Trial Group, 803
 Neilsen GA, 671
 Nelson MB, 306
 Nerovjina R, 680
 Ness RB, 71
 Newman SB, 306, 531
 Ng L-K, 896
 Niccolai LM, 75
 Niesters HGM, 639
 Nikitina M, 680
 Nishimura M, 629
 Nsuami M, 367, 728
 Nyamukapa C, 779
- O**
 O'Brien ME, 731
 Oh MK, 49, 689
 Oksanen H, 120
 Ólafsson JH, 249
 Olcén P, 205
 O'Leary M, 362
 Olmsted SS, 257
 Osterhaus ADME, 639
 Otero L, 280, 292, 395
 Otto B, 671
 Ovaskainen OT, 388
 Owens ML, 124
- P**
 Paavonen J, 120, 737
 Padian NS, 556
 Paffel JM, 872
 Page-Shafer K, 331, 919
 Pajanidi J, 680
 Palacio V, 280
 Palefsky JM, 575
 Palma S, 10

- Parker KA, 39
 Partohudoyo S, 671
 Patel D, 216
 Patnaik JL, 15, 562
 Patten J, 671
 Patton DL, 568
 Paukku M, 120
 Paul C, 818
 Paz-Bailey G, 320
 Pech N, 6
 Perdue T, 425
 Peterman TA, 75, 83, 731
 Petrovichev N, 680
 Pettifor A, 455
 Pfister JR, 797
 Pigott D, 335
 Platt L, 46
 Platt R, 866
 Podistov J, 680
 Potterat JJ, 89, 490
 Poumerol G, 362
 Pourbohloul B, 297
 Preiksaitis J, 33
 Price MA, 516
 Primary Care STI Study Group
 (GITSAP), 876
 Prince MA, 593
 Proyecto Concoria Collaborative
 Group, 593
 Pshepurko A, 680
 Puolakkainen M, 120
- Q**
 Quer J, 470
 Quinn TC, 539, 769
 Quint W, 137
- R**
 Rabe LK, 568
 Ramarokoto C-E, 262
 Ramirez-Arcos S, 443
 Ramos BPL, 195
 Ransom RL, 49
 Raphael TL, 614
 Ratelle S, 866
 Rattray C, 575
 Ravaoalimalala EV, 262
 Raveh D, 835
 Ray K, 523
 Read RR, 315
 Regional Infertility Prevention Pro-
 gram, 472
 Rein MF, 348
 Rekart ML, 297
 Renjifo B, 187
 Reppucci ND, 348
 Reunala T, 737
 Rhodes SD, 449
 Rice P, 71
 Richardson-Alston G, 75, 731
 Richardson E, 880
 Richter HE, 71
 Rietmeijer CA, 15, 399, 562, 659
 Rinaldi J, 874
 Roberts CM, 797
 Roberts JN, 226
 Rogers C, 433
 Rohan LC, 257
 Rohan TE, 581
 Rojas C, 246
 Romanowski B, 33, 226
 Rompalo A, 143, 533
- Rosana Y, 25
 Rose E, 57, 211, 634
 Rosenthal SL, 752, 774, 801, 854
 Ross MW, 110
 Rothenberg R, 478
 Rotheram MJ, 803
 Rothman RE, 143
 Rousseau M-C, 581
 Rousset D, 262
 Ruben M, 443
 Rudy E, 411, 685
 Rust G, 723
 Ruutu P, 737
 Ryan CA, 39
- S**
 Sadan O, 835
 Safarova E, 39
 Sahin-Hodoglugil NN, 455
 Saka T, 629
 Salas EV, 195
 Salcedo C, 395
 Sam NE, 187, 588
 Samra Z, 794, 835
 Samson ET, 671
 Sánchez C, 280, 292
 Sánchez J, 273
 Sánchez-Zamorano L, 549
 Sanders WM, 512
 Sansom S, 685
 Santelli J, 719
 Santopietro R, 680
 Satcher D, 723
 Sauca G, 395
 Sauder DN, 124
 Schachter J, 575, 905
 Schaffzin JK, 700
 Scherf E, 794
 Schiffman M, 575
 Schillinger JA, 49
 Schim van der Loeff M, 483
 Schwarcz S, 609
 Seattle Young Men's Survey Team,
 425
 Secura GM, 425
 Sellors J, 345, 880
 Shabalova I, 680
 Shafer M-A, 545
 Shakarishvili A, 39
 Shao JF, 187
 Shiboski SC, 556
 Shimizu T, 629
 Short MB, 752, 854
 Siddiqi O, 262
 Silverthorn M, 134
 Simões-Barbosa A, 694
 Simpson T, 689
 Sinclair MF, 650
 Singh A, 315, 497
 Sitati S, 137
 Sizemore JM, 512
 Skinner RB, 124
 Smith A, 886
 Snijders PJF, 788
 Soper DE, 71
 Sosa J, 10, 443
 Sozaeva L, 680
 Spear SJ, 797
 Spencer NE, 83
 St. Lawrence JS, 39, 490
 Stamm C, 71
- Stamm WE, 160, 357
 Stanberry LR, 752, 801, 854
 Steingrímsson Ó, 249
 Stein ZA, 433
 Stephan K, 713
 Sternberg M, 49, 320
 Steyaert S, 137
 Stiffman M, 30
 Stine K, 890
 Stray-Pedersen B, 588
 Strickler HD, 575
 Strine T, 685
 Sturm AW, 1, 149, 241
 Sturm PDJ, 241
 Succop PA, 752
 Suchland RJ, 160, 357
 Sudigdoadi S, 25
 Sugai K, 575
 Su L, 246
 Sullivan EA, 362
 Supawitkul S, 320
 Sutama IN, 671
 Sutton TL, 901
 Su X, 178
 Svensson LA, 114
 Sweat MD, 149
 Sweet RL, 71
 Syrjänen K, 680
 Syrjänen S, 680
- T**
 Tabrizi S, 362, 886
 Taha TE, 185
 Takahashi S, 629
 Takeyama K, 629
 Taleo H, 362
 Tambis JA, 661
 Tanda H, 629
 Tang Y, 866
 Tao G, 866
 Tapsall JW, 178
 Tasker SA, 713
 Tawes J, 64
 Taylor-Robinson D, 129
 Temmerman M, 137
 Terndrup T, 335
 Thiede H, 425
 Thomas AG, 713
 Thomas B, 129
 Tikhonova L, 39
 Timpson S, 571
 Tosi P, 680
 Totten PA, 756
 Trepka MJ, 914
 Tsidaeva I, 680
 Tsui H, 600, 620
 Tsukamoto T, 629
 Tulloch S, 64
 Turkheimer E, 348
 Turner KR, 331
- U**
 Urassa M, 779
 Uribe-Salas F, 266
- V**
 Valdés EA, 10
 Valleroy L, 425
 Valtrex HS230017 Study Group,
 226
 van den Brule AJC, 593
 van der Meijden WI, 639
- van der Snoek EM, 639
 van Doornum GJJ, 639
 Van Dyck E, 284
 Van Griensven F, 320
 Van Looveren M, 25
 Vanmali T, 241
 Van Marck E, 137
 Van Renterghem L, 137
 Vansteelandt S, 137
 Vaovola G, 664
 Varela JA, 280, 292
 Vázquez F, 280, 292, 395
 Vázquez JA, 395
 Veenstra DL, 99
 Villa LL, 581
 Villar H, 395
 Vlahov D, 199
 Vuylsteke BL, 284
- W**
 Wald A, 174, 310, 713, 890
 Wallace MR, 713
 Walsh J, 455
 Walter E, 809
 Waltje A, 134
 Wang Q, 600
 Wang SA, 528
 Ward K, 609
 Watts D, 273
 Wegner S, 713
 Weinberg M, 645
 Weisbord JS, 914
 Weiss HL, 850
 West B, 483
 Whelan M, 866
 Whitten KL, 348
 Whittington WLH, 49, 160, 742
 Wiktor SZ, 284
 Wilkinson D, 1, 241
 Williams BG, 149
 Williams I, 919
 Williams ML, 110, 571
 Wilson TE, 809
 Wingood GM, 57, 211, 634
 Wong E, 331, 919
 Wong T, 497
 Wong W, 661
 Woodcox V, 880
 Woods R, 455
 Workowski KA, 528
 Wu Z, 803
- X**
 Xavier J, 694
- Y**
 Yacoub W, 497
 Yarber W, 134
 Yeh JM, 369
 Yin Y, 327, 803
 Yokoe D, 866
 Yuan W, 600
- Z**
 Zakharenko S, 680
 Zakharova T, 680
 Zenilman JM, 143
 Zhang G, 914
 Zimba D, 516
 Zuma K, 149

INDEX OF SUBJECTS

A

- Acquired immunodeficiency syndrome. *See* Human immunodeficiency virus infection
- Adjudicated African American adolescents, risk behavior of, 634
- Adolescents
- acceptability of urine screening for gonorrhea and chlamydia in, 850
 - adjudicated African American, risk behavior of, 634
 - dual use of condoms and hormonal contraceptives by, 719
 - female
 - nonexclusivity in romantic relationships of, 752
 - topical microbicide use by, 854
 - genital herpes in, HSV type 1 as predominant cause of, 797
 - high-risk, discordant sexual partnerships of, 234
 - HSV-2 infection in, sexual and demographic risk factors for, in Mexico, 549
 - pregnant African American
 - continued risky sex among, 57, 211, 214 (editorial)
 - with older partners, STD prevalence among, 211, 214 (editorial)
 - risk behaviors of, in Thailand, 320
 - screening recommendations for, 367 (letter)
- Africa. *See also specific countries*
- bacterial vaginosis in
 - rapid diagnostic kit for, 483
 - treatment algorithms for sex workers in, 284
 - cost-effectiveness of diagnosis and treatment protocols for chlamydia and gonorrhea in, 455
 - genital ulcer disease in, etiology and HIV co-infection in, 114
 - HIV-1 transmission in, migration and, 149
 - HIV prevalence in, 183, 185 (letters)
 - HIV risk factors in, 183, 185 (letters), 262
 - HPV distribution in family planning clinic attendees in, 137
 - HSV type 2 infection in
 - prevalence of, 187, 588
 - risk factors for, 187, 262
 - participatory mapping of sex trade in, 664
 - sex workers in, STD treatment algorithms for, 284
 - syndromic management in, role of community pharmacists in, 609
 - uneven HIV prevalence in, 779
- African Americans. *See also* Race/ethnicity
- adjudicated adolescent, risk behavior of, 634
 - gay, hepatitis B vaccination in, 449, 685
 - pregnant adolescent
 - continued risky sex among, 57
 - with older partners, STD prevalence among, 211, 214 (editorial)
- Age
- cervical infection with multiple HPV types and, 581
 - female, condom use and, 216
 - partner
 - in discordant adolescent sex partnerships, 234
 - STD prevalence in adolescent girls and, 211, 214 (editorial), 234
- AIDS. *See* Human immunodeficiency virus infection
- Anal nodular herpes simplex virus infection, in AIDS, 157
- Anal warts, imiquimod 5% cream for, 124
- Anogenital warts
- 5% imiquimod cream for, 124
 - frequently asked questions about, 193
- Antibiotics
- prophylactic, for syphilis, 844
 - topical, acceptability of to adolescent girls, 854
- Antimicrobial resistance, of *N. gonorrhoeae*
- in Canada, 896
 - in Cuba, 11, 443
 - in India, 523
 - in Indonesia, 25, 178
 - in Spain, 395
- Antiretroviral therapy
- adherence to, transmission risk behaviors and, 399
 - availability of, impact of on risk behaviors, 562, 765
- Argentina, HPV infection in, prevalence of in females, 593

Army recruits

- female, chlamydia prevalence in, 539, 545 (editorial)
 - male, HIV-infected, human herpesvirus-8 infection in, 713
- ASTDA awards, 477, 478
- Australia, gonorrhea and chlamydia screening in, at male-only saunas, 886
- Azithromycin
- for chlamydial infection, partner-delivered partner treatment with, 49
 - for incubating syphilis, cost-effectiveness of, 502
 - N. gonorrhoeae* resistance to, in Cuba, 443

B

- Bacterial vaginosis
- glycosidase and proteinase activity in, 257
 - HSV-2 infection and, 405
 - in pregnancy, management of, 645
 - rapid diagnostic kit for, in Gambia, 483
 - syndromic management of, with/without HIV-1 coinfection, 1
 - treatment algorithms for, for sex workers, in Côte d'Ivoire, 284
- Barrier contraceptives. *See also* Condom use
- acceptability and product choice as indicators of use of, 556
- Bathhouses, male-only, gonorrhea and chlamydia screening in, 886
- Belarus, sexual habits and HPV infection in females in, 680
- Birth control pills, condom use with
- by adolescents, 719
 - by HIV-infected vs. non-HIV-infected women, 809
- Brazil, HIV risk factors and prevalence in, 166
- Bridge members, of adolescent sexual networks, 234

C

- Canada
- gonorrhea outbreak in, 497
 - N. gonorrhoeae* drug resistance in, 896
 - syphilis outbreak in, patient characteristics with male-to-male vs. heterosexual acquisition in, 310
- Candidal vaginitis, treatment algorithms for, for sex workers, in Côte d'Ivoire, 284
- Capture-recapture methodology, in sex trade mapping and sex worker enumeration, in Madagascar, 664
- Caribbean, drug-resistant *N. gonorrhoeae* in, 10, 443
- CDC case definition, of pelvic inflammatory disease, predictive value of clinical diagnostic codes for, 866
- Centers for Disease Control and Prevention (CDC), treatment guidelines of for chlamydia, adherence to in managed care organizations, 30
- need for revision of, 528 (letter)
- Cervical gonococcal infections, in Indonesian sex workers, 671
- Cervical neoplasia grade, STD coinfections and, in Jamaica, 575
- Cervicovaginal secretion collection, self-sampling methods for, 107, 306, 769, 880
- China. *See also* Hong Kong
- market vendors in, STD prevalence and characteristics in, 803
 - STD/HIV prevention in, needs assessment for, 600
 - syndromic management of male STDs in, 327
- Chlamydial heat-shock protein 60 kDa antibodies, 157
- in chronic nongonococcal urethritis, 129
- Chlamydial infection
- adolescent risk behaviors and, in Thailand, 320
 - CDC guidelines for, adherence to in managed care organizations, 30
 - cervical neoplasia grade and, in Jamaica, 575
 - cervicovaginal specimen collection for, self-sampling methods for, 107, 306, 769, 880
 - contact tracing for, genotyping and, 205
 - cost-effectiveness of diagnosis and treatment protocols for, in Africa, 455
 - gonococcal coinfection and, in young women, 472
 - HPV infection and, in men who have sex with men, 639
 - importation of, spatial bridging in, 742, 750 (editorial)
 - in incarcerated women
 - preferred sampling methods of, 306
 - surveillance for, 64
 - increased incidence of, in Finland, 737

- male, epidemiologic trends in, in Spain, 280
 - molecular epidemiology of, in Iceland, 249
 - partner notification for, low coverage of, 490
 - patient-delivered partner therapy with azithromycin for, 49
 - patient-delivered therapy for, 509
 - in pregnant African American teens with older partners, 211, 214 (editorial)
 - prevalence of
 - in female Army recruits, 539, 545 (editorial)
 - in female emergency department patients, 335
 - in Finland, 737
 - in Indonesian sex workers, 671
 - in Mexican sex workers, 195
 - in pregnant women, in Vanuatu, 362
 - in ROTC cadets, 901
 - screening for. *See also* Screening
 - in adolescents, 367 (letter)
 - age range for, 120
 - in asymptomatic men, ligase chain reaction with/without leukocyte esterase test for, 99
 - in community based mobile clinic, 654
 - in Indonesian sex workers, 671
 - at male-only saunas, 320
 - risk factor vs. clinically based, 901
 - sentinel site surveillance for, 20
 - serovar-clinical manifestations correlation in, 160
 - syndromic management of, in China, 327
 - urine testing for
 - in males, 345
 - self-sampling methods for, 306, 769
 - Chlamydia trachomatis*
 - genotyping of, contact tracing and, 205
 - serovars of, longitudinal assessment of, 357
 - Cigarette smoking, HSV-2 infection and, 405
 - Ciprofloxacin, gonococcal resistance to. *See also* Antimicrobial resistance
 - in India, 523
 - in Spain, 395
 - Circumcision, HSV-2 infection in females and, 405
 - Clinic attendees. *See* Family planning clinic attendees; Sexually transmitted disease clinic attendees
 - College students. *See also* Adolescents
 - acceptability of STD vaccination in, 774
 - genital herpes in, HSV type 1 as predominant cause of, 797
 - Commercial sex workers. *See* Sex workers
 - Community-based screening, effectiveness of, 654, 659 (editorial)
 - Community pharmacists, as treatment providers
 - in Peru, 379
 - in South Africa, 609
 - Compliance, with antiretroviral therapy, transmission risk behaviors and, 399
 - Concurrency, quantitative assessment of, 6
 - Condom use. *See also* Risk behavior/factors
 - acceptability and product choice as indicators of, 556
 - by adjudicated African American adolescents, 634
 - female condoms
 - acceptability and product choice as indicators of, 556
 - patterns and predictors of, 91, 556
 - use-effectiveness of, 433, 440 (editorial)
 - by HIV-infected persons, in rural areas, 134
 - with hormonal contraceptives
 - by adolescents, 719
 - by HIV-infected vs. non-HIV-infected women, 809
 - by older women, 216
 - promotion of, in China, 600
 - by sex workers, in Peru, 273
 - Condylomata acuminata
 - frequently asked questions about, 193
 - imiquimod 5% cream for, 124
 - Contact tracing. *See* Partner notification
 - Contraceptives
 - barrier. *See also* Condom use
 - acceptability and product choice as indicators of use of, 556
 - oral, condom use with
 - by adolescents, 719
 - by HIV-infected vs. non-HIV-infected women, 809
 - Core groups
 - geographic stability of, 825 (editorial)
 - stability of sexual behavior in, 818
 - Correspondence, 183, 185, 367, 368, 526, 528, 531
 - Cost, average lifetime, of pelvic inflammatory disease, 369
 - Cost effectiveness
 - of azithromycin, for incubating syphilis, 502
 - of diagnosis and treatment protocols for chlamydia and gonorrhea, in Africa, 455
 - of syndromic management in pharmacies
 - in Peru, 379
 - in South Africa, 609
 - Côte d'Ivoire, treatment algorithms for bacterial vaginosis in sex workers in, 284
 - Counseling, telephone, in Italy, 707
 - Cross-border sexual networks, in Hong Kong, 827
 - Cuba, drug-resistant *N. gonorrhoeae* in, 10, 443
- D**
- Day laborers, urban immigrant, STD prevalence among, 661
 - Detained African American adolescents, risk behavior of, 634
 - Developing countries. *See also* specific countries
 - adolescent risk behaviors in, 320
 - bacterial vaginosis in
 - rapid diagnostic kit for, 483
 - treatment algorithms for sex workers in, 284
 - cost-effectiveness of diagnosis and treatment protocols for chlamydia and gonorrhea in, 455
 - drug-resistant *N. gonorrhoeae* in, 10, 178, 443
 - genital ulcer disease in, etiology and HIV co-infection in, 114
 - HIV-1 transmission in, migration and, 149
 - HIV prevalence in, 183, 185 (letters)
 - HIV risk factors in, 187, 262
 - HPV distribution in family planning clinic attendees in, 137
 - HSV type 2 infection in
 - prevalence of, 187, 588
 - risk factors for, 187, 262
 - laboratory testing for STDs and HIV infection in, 905
 - N. gonorrhoeae* antimicrobial susceptibility in, 25, 178
 - participatory mapping of sex trade in, 664
 - rapid diagnostic kit for bacterial vaginosis in, 483
 - sexual partnership and concurrency in, quantitative assessment of, 6
 - sex workers in
 - sociodemographic dynamics and STDs in, 266
 - STD treatment algorithms for, 284
 - STD prevalence in pregnancy in, 362
 - STD prevention in, for sex workers, 273
 - syndromic management in, role of community pharmacists in, 609
 - syndromic management in pharmacies in, 379, 609
 - syndromic management of male STDs in, 327
 - uneven HIV prevalence in, 779
 - Diagnostic testing, in developing countries, 905
 - Discordant sexual partners
 - of high-risk adolescents, 234
 - of pregnant African American teens, 211, 214 (editorial)
 - Douching
 - early-onset, health beliefs and high-risk behavior and, 689
 - HSV-2 infection and, 405
 - reasons for continuing or stopping, 71
 - Drug resistance. *See* Antimicrobial resistance
 - Drug use. *See* Substance use/abuse
 - Dry swab sampling
 - for HPV polymerase chain reaction assay, in males, 246
 - self-performed, for cervicovaginal specimen collection, 107, 306, 769, 880

E

- Economic factors. *See under* Cost
 Editorials, 10, 46, 90, 214, 232, 440, 659, 750, 801, 825
 Education, patient, for HPV infection, 193
 ELISA, time course to seroconversion by, in HSV-1 infection, 310
 Emergency department patients, female, gonorrhea and chlamydia prevalence in, 335
 Emergency-department screening, in inner city vs. urban sites, 143
 Ethnicity. *See* Race/ethnicity

F

- Family planning clinic attendees
 female condom use among, 91
 HPV distribution in, 137
 Female condoms. *See also* Condom use
 acceptability and product choice as indicators of use of, 556
 patterns and predictors of use of, 91, 556
 use-effectiveness of, 433, 440 (editorial)
 FemExam, for bacterial vaginosis, 483
 Financial factors. *See under* Cost
 Finland, chlamydial infection in
 increased incidence of, 737
 screening for, 120
 Fluoroquinolones, resistance to. *See also* Antimicrobial resistance
 CDC treatment guidelines and, 528 (letter)

G

- Gambia, rapid diagnostic kit for bacterial vaginosis in, 483
 Gap length, STD transmission and, 221
 Gays. *See* Men who have sex with men
 Genital herpes. *See* Herpes simplex virus infection
 Genital ulcer disease, 124
 HIV coinfection and
 in Tanzania, 114
 treatment response and, 241
 HSV-2 as etiologic agent of, in Tanzania, 114
 syndromic management of, in China, 327
 Genital warts
 frequently asked questions about, 193
 imiquimod 5% cream for, 124
 Geographic stability, of core groups, 825 (editorial)
 Glycosidase activity, in bacterial vaginosis, 257
 Gonorrhea/gonococcal infection
 adolescent risk behaviors and, in Thailand, 320
 chlamydia coinfection in, in young women, 472
 detection of HPV on external genitalia of males with, 629
 drug-resistant
 in Canada, 896
 in Cuba, 11, 443
 in India, 523
 in Indonesia, 25, 178
 in Java, Indonesia, 25
 in Spain, 395
 etiologic and epidemiologic trends in, in Spain, 280
 HPV infection and, in men who have sex with men, 639
 importation of, spatial bridging in, 742, 750 (editorial)
 in incarcerated women, surveillance for, 64
 outbreak of, in northern Alberta, Canada, 497
 partner notification for, low coverage of, 490
 prevalence of
 in female emergency department patients, 335
 in Indonesian sex workers, 671
 in pregnant women, in Vauatu, 362
 in women 15 to 24, 472
 rectal, risk factors for, HIV status and, 813
 screening for. *See also* Screening
 in adolescents, 367 (letter)
 in Indonesian sex workers, 671
 at male-only saunas, 320
 in pregnancy, 728
 syndromic management of
 in China, 327

- trichomoniasis treatment in, in Malawi, 516
 treatment algorithms for, for sex workers, in Côte d'Ivoire, 284
 urine testing for, acceptability of to adolescents, 850
 Guatemala, sex workers in, sociodemographic dynamics and STDs in, 266

H

- Health-seeking behavior, of male STD clinic attendees with/without regular doctors, 512
 Hepatitis, vaccination for, hepatitis A/B vs. hepatitis B vaccine for, 859
 Hepatitis A, in men who have sex with men
 prevalence of, 425
 risk factors for, 425
 vaccination for, 411, 425, 685, 859
 Hepatitis B
 in men who have sex with men
 prevalence of, 425
 risk factors for, 425
 vaccination in, 411, 425, 449, 685, 859
 risk factors and immunity for, in STD clinic attendees, 914
 Hepatitis C
 in men who have sex with men, 425
 screening for, in STD clinic attendees, 340
 seroprevalence of and risk behaviors for, in STD clinic attendees, 33
 sexual transmission of
 after IUD removal, 470
 rates of, 919
 HerpeSelect ELISA, time course to seroconversion by, in HSV-1 infection, 310
 Herpes simplex virus infection
 genital ulcer disease as, in Tanzania, 114
 HPV infection and, in men who have sex with men, 639
 nodular perianal, in AIDS, 157
 prevalence of and risk factors for, in lesbians, 890
 suppressive vs. episodic treatment for, patients' preference for, 226, 232 (editorial)
 type 1
 in college students, 797
 in first episode, 801 (editorial)
 in Israel, 794
 natural history of, 174
 time course of seroconversion by ELISA in, 311
 type 2
 cervical neoplasia grade and, in Jamaica, 575
 in persons seeking repeat HIV testing, 331
 in pregnant Israeli women, 835
 prevalence of, in Tanzania, 187
 risk factors for
 in females, 405
 in Mexican adolescents and young adults, 549
 in Tanzania, 187
 Highly active antiretroviral therapy
 adherence to, transmission risk behaviors and, 399
 impact of on risk behaviors, 399, 562, 764
 Hispanic day laborers, urban, STD prevalence among, 661
 HIV infection. *See* Human immunodeficiency virus infection
 Homosexuals. *See* Lesbians; Men who have sex with men
 Hong Kong. *See also* China
 behavioral surveillance surveys of male clients of female sex workers in, 620
 cross-border sexual networks in, 827
 Hormonal contraceptives, condom use with
 by adolescents, 719
 by HIV-infected vs. non-HIV-infected women, 809
 Human herpesvirus-8 infection
 in HIV-infected soldiers, 700
 in injection drug users, 199
 Human immunodeficiency virus infection
 adolescent risk behaviors and, in Thailand, 320
 anonymous counseling and testing sites for, treatment of asymptomatic STDs at, 874
 counseling and testing sites for, treatment of asymptomatic STDs at, 874
 dual contraceptive use and, 809

- HAART for, impact of on risk behaviors, 399, 562, 765
 human herpes type 8 infection and, in soldiers, 700
 mortality in, as cause of declining syphilis rates, 419
 nodular perianal HSV infection in, 157
 partner notification for
 effects of on sexual behaviors and relationship stability, 75, 83
 low coverage of, 490
 prevalence of, in Malawi, 183, 185 (letters)
 risk behaviors/factors for
 in Brazil, 166
 changing perspectives on, 764
 impact of HAART on, 562, 764
 in Madagascar, 262
 in Malawi, 183, 185 (letters)
 in rural areas, 134
 screening for. *See* Screening
 seropositivity for
 disclosure of by patient, 731
 dual condom use by women and, 809
 risk behaviors for rectal gonorrhea and, 813
 among STD clinic attendees, in Spain, 876
 symptomatic management of bacterial vaginosis in, 1
 testing for, perceptions of risk and, 764
 transmission of, effect of migration on, in South Africa, 149
 treatment response in genital ulcer disease and, 241
 trichomoniasis in, associated factors in, 839
 uneven prevalence of, in Africa, 779
 Human papillomavirus DNA, detection of on external genitalia of males with urethritis, 629
 Human papillomavirus infection
 asymptomatic, in males with urethritis, 629
 cervical, in Spain, 788
 cervical neoplasia grade in, STD coinfections and, in Jamaica, 575
 in family planning clinic attendees, in Kenya, 137
 frequently asked questions about, 193
 with multiple HPV types, age and cytologic abnormalities and, 581
 PCR assay for, sampling methods for, 246
 prevalence of, in Argentine women, 593
 Human T-cell lymphotropic virus type 1, cervical neoplasia grade and, in Jamaica, 575
- I**
 Iceland, chlamydial infection in, molecular epidemiology of, 249
 Imiquimod 5% cream, for external genital and perianal warts, 124
 Immigrant day laborers, urban, STD prevalence among, 661
 Immunization
 for hepatitis
 hepatitis A/B vs. hepatitis B vaccine for, 859
 for men who have sex with men, 411, 425, 449, 685
 among STD clinic attendees, 914
 for STDs, acceptability of among college students, 774
 Incarcerated persons
 African American adolescent, risk behavior of, 634
 female
 chlamydia in
 preferred sampling methods for, 306
 surveillance for, 64
 epidemiologic study on STDs in, 531 (letter)
 gonorrhea in, surveillance for, 64
 India, ciprofloxacin- and penicillin-resistant *N. gonorrhoeae* in, 523
 Indonesia
 laboratory testing for STDs and HIV infection in, 905
 N. gonorrhoeae antimicrobial susceptibility in, 25, 178
 sex workers in
 gonorrhea/chlamydia screening in, 671
 STD prevalence in, 671
 Injection drug use
 HIV prevalence and, in Brazil, 166
 human herpesvirus type 8 infection and, 199
 by sex workers, in Russia, 46 (editorial)
 Internet, as information resource, for at-risk populations, 15
 Intervention scenarios, mathematical tools for, 388
- Intrauterine device, hepatitis C transmission after removal of, 470
 Intravenous drug use. *See* Injection drug use
 Israel
 genital herpes in, HSV type 1 as predominant cause of, 794
 HSV type 2 in pregnant women in, 835
 Italy, telephone hotline in, 707
- J**
 Jamaica, cervical neoplasia grade in, STD coinfections and, 575
 Java, *N. gonorrhoeae* antimicrobial susceptibility in, 25
- K**
 Kenya, HPV distribution in family planning clinic attendees in, 137
 Klausner, Jeffrey, ASTDA Young Investigator Award recipient, 477
- L**
 Laboratory testing, in developing countries, 905
Lactobacillus crispatus capsules, single-use safety study of, 568
 Latino immigrant day laborers, urban, STD prevalence among, 661
 Latvia, sexual habits and HPV infection in females in, 680
 Lesbians, HSV infection in, prevalence of and risk factors for, 890
 Letters to editor, 183, 185, 367, 368, 526, 528, 531, 531/531
 Leukocyte esterase test, for chlamydial infection, in asymptomatic males, 99
 Lice, pubic, epidemiology of, 292
 Ligase chain reaction, with/without leukocyte esterase test, for chlamydial infection, in asymptomatic males, 99
- M**
 Madagascar
 HIV risk factors in, 262
 participatory mapping of sex trade in, 664
 Malawi
 HIV prevalence and risk factors in, 183, 185 (letters)
 syndromic treatment of urethritis in, trichomoniasis treatment in, 516
 Male-to-male sexual activity. *See* Men who have sex with men
 Managed care organizations, adherence to CDC guidelines for chlamydial infections in, 30
 Mapping, of sex trade, in Madagascar, 664
 Mathematical tools, for assessing effectiveness of intervention scenarios, 388
 Men who have sex with men
 gonorrhea and chlamydia screening in, 886
 at male-only saunas, 886
 hepatitis vaccination for, 411, 425, 449, 685, 859
 HPV infection in, STD coinfection and, 639
 pubic lice in, 292
 risk behaviors of
 availability of HAART and, 562
 in Canadian syphilis outbreak, 315
 at sex resorts, 909
 self-reported sexual activity of, 526 (letter)
 syphilis outbreak among, 872
 young African American, hepatitis B vaccination in, 449
 Metronidazole, for trichomoniasis, in syndromic treatment of urethritis, in Malawi, 516
 Mexico
 chlamydia prevalence in, 195
 HSV-2 infection in, sexual and demographic risk factors for, in adolescents and young adults, 549
 sex workers in, sociodemographic dynamics and STDs in, 266
 urban day laborers from, STD prevalence among, 661
 Microbicides
 N. gonorrhoeae resistance to
 in Canada, 896
 in Cuba, 11, 443
 in India, 523
 in Indonesia, 25, 178
 in Spain, 395
 prophylactic, for syphilis, 844
 topical, acceptability of to adolescent girls, 854
 Microwell-plate-based PCR assay, for *Mycoplasma genitalium*, 756
 Migrant laborers, urban Latino, STD prevalence among, 661

Military recruits

- female, chlamydia prevalence in, 539, 545 (editorial)
- male, HIV-infected, human herpesvirus-8 infection in, 713
- Mobile community-based screening, effectiveness of, 654, 659 (editorial)
- Mycoplasma genitalium*, microwell-plate-based PCR assay for, 756

N

- Neisseria gonorrhoeae*, antimicrobial susceptibility of
 - in Canada, 896
 - in Cuba, 11, 443
 - in India, 523
 - in Indonesia, 25, 178
 - in Spain, 395
- Netherlands, HPV infection in gay men in, STD coinfection and, 639
- New Independent States of Soviet Union, sexual habits and HPV infection in females in, 680
- Nodular perianal herpes simplex virus infection, in AIDS, 157
- Nongonococcal urethritis
 - chronic, chlamydial hsp60 antibodies in, 129
 - detection of HPV DNA on external genitalia of males with, 629
- Notification. *See* Partner notification

O

- Oral contraceptives, condom use with
 - by adolescents, 719
 - by HIV-infected vs. non-HIV-infected women, 809

P

- Papanicolaou test, for trichomoniasis, 694
- Parran Award Lecture, 477, 478
- Partner age
 - in discordant adolescent sex partnerships, 234
 - STD prevalence in adolescent girls and, 211, 214 (editorial), 234
- Partner notification
 - barriers to, 90 (editorial)
 - for chlamydial infection, genotyping and, 205
 - for HIV and syphilis, effects of on sexual behaviors and relationship stability, 75, 83
 - low coverage for gonorrhea, chlamydial infection, and HIV infection in, 490
- Patient-delivered therapy, for chlamydial infection, 509
- Patient education, for HPV infection, 193
- Patient-performed sample collection, for cervicovaginal specimens, 107, 306, 769, 880
- Pelvic inflammatory disease
 - average lifetime cost of, 369
 - clinical diagnostic codes for CDC case definition of, predictive value of, 866
- Penicillin. *See also* Antibiotics
 - N. gonorrhoeae* resistance to
 - in Canada, 896
 - in Cuba, 10, 443
 - in India, 523
 - in Indonesia, 25, 178
 - in Spain, 395
- Perianal nodular herpes simplex virus infection, in AIDS, 157
- Perianal warts, imiquimod 5% cream for, 124
- Peru
 - cost-effectiveness of syndromic management in pharmacies in, 379
 - STD prevention in, for sex workers, 273
- Pharmacies, syndromic management in
 - in Peru, 379
 - in South Africa, 609
- Phthirus pubis*, epidemiology of, 292
- Polymerase chain reaction assay
 - for HPV, sampling methods for, 246
 - microwell-plate-based, for *Mycoplasma genitalium*, 756
- Pregnancy
 - in African American teens, older partners and STD prevalence among, 211, 214 (editorial)
 - bacterial vaginosis in
 - management of, 645

- preterm labor and, 645
- continued risky sex during, among African American adolescents, 57
- gonorrhea screening in, 728
- HSV-2 infection in, in Israel, 835
- STD prevalence in, in Vanuatu, 362
- Preterm labor, bacterial vaginosis and, 645
- Prevention
 - Internet information sources for, 15
 - needs assessment for, in China, 600
 - in sex workers, in Peru, 273
 - state policy support for, 614
- Prisoners
 - African American adolescent, risk behavior of, 634
 - female
 - chlamydial infection in
 - preferred sampling methods for, 306
 - surveillance for, 64
 - epidemiologic study on STDs in, 531 (letter)
 - gonorrhea in, surveillance for, 64
- Prostitutes. *See* Sex workers
- Protease inhibitors, incidence of trichomoniasis in HIV infection and, 839
- Proteinase activity, in bacterial vaginosis, 257
- Psychosocial factors, in vaccination for hepatitis C, in young African American gay men, 449
- Pubic lice, epidemiology of, 292
- Public health clinic attendees. *See* Sexually transmitted disease clinic attendees

R

- Race/ethnicity. *See also* African Americans
 - chlamydia and gonorrhea in incarcerated women and, 64
 - concordance between sexual behavior and sexual identity and, 110
 - emergency-department screening in inner city vs. urban sites and, 143
 - STD prevalence among urban day laborers and, 661
- Reactor grids, in syphilis surveillance, 650
- Rectal gonorrhea, risk factors for, HIV status and, 813
- Reporting, of male-to-male sexual activity, 526 (letter)
- Risk behaviors/factors. *See also* Condom use; Sexual behavior; Substance use/abuse
 - of adjudicated African American adolescents, 634
 - in cross-border sexual networks, in Hong Kong, 827
 - discordant sexual partners and, 234
 - early-onset douching and, 689
 - effects of partner notification on, 75, 83
 - emotional experience of intercourse as, 348
 - of females in New Independent States of Soviet Union, 680
 - heterogeneity of, treatment planning and, 388
 - for HIV infection
 - in Brazil, 166
 - changing attitudes toward, 764
 - impact of HAART on, 399, 562, 764
 - in Madagascar, 262
 - in Malawi, 183, 185 (letters)
 - in rural areas, 134
 - in HSV-2 infection, in females, 405
 - of males with/without regular doctors, 512
 - of men who have sex with men, at sex resorts, 909
 - in pregnant African American teens, 57, 211, 214 (editorial)
 - stability of, in birth cohort, 818
 - in Thailand, 320
- Risk spaces, core group concept and, 825 (editorial)
- Rothenberg, Richard, Thomas Parran Award recipient, 477, 478
- Russia
 - sexual habits and HPV infection in females in, 680
 - sex workers in
 - injection drug use by, 46 (editorial)
 - social organization of, 39

S

- Sample collection, cervicovaginal, patient-performed, 107, 306, 769, 880
- Sauna, male-only, gonorrhea and chlamydia screening in, 886
- Screening

- for chlamydia
 - in adolescents, 367 (letter)
 - age range for, 120
 - in asymptomatic men, ligase chain reaction with/without leukocyte esterase test for. *See* Race/ethnicity
 - in community based mobile clinic, 654, 659 (editorial)
 - at male-only saunas, 886
 - risk factor vs. clinically based, 901
- emergency-department, in inner city vs. urban sites, 143
- for gonorrhea
 - in Indonesian sex workers, 671
 - at male-only saunas, 886
 - in pregnancy, 728
- for hepatitis C, in STD clinic attendees, 340
- for Medicaid patients, 723
- mobile community-based, effectiveness of, 654, 659 (editorial)
- for Peruvian sex workers, 273
- Self-sampling, for cervicovaginal secretions, 107, 306, 769, 880
- Sentinel site surveillance, for chlamydial infection, 20
- Sex resorts, for gay men, risk behavior at, 909
- Sex trade. *See also* Sex workers
 - participatory mapping of, in Madagascar, 664
- Sexual activity, male-to-male. *See also* Men who have sex with men
 - reporting of, 526 (letter)
- Sexual behavior. *See also* Risk behaviors/factors
 - concordance of with sexual identity, racial/ethnic variations in, 110
 - female adolescent, nonexclusivity in romantic relationships in, 752
 - of females in New Independent States of Soviet Union, 680
 - of older women, 216
 - stability of, in birth cohort, 818
- Sexual concurrency, quantitative assessment of, 6
- Sexual debut, douching and, 689
- Sexually transmitted disease clinic attendees
 - female condoms use by, 91
 - hepatitis C screening in, 340
 - hepatitis C seroprevalence and risk behaviors in, 33
 - HIV seroprevalence in, 876
 - Internet use by, 33
 - pubic lice in, epidemiology of, 292
 - risk factors and immunity for hepatitis B in, 914
 - treatment of symptomatic STDs at, 512
 - with/without regular doctors, STD burden and risk in, 512
- Sexually transmitted diseases. *See also* specific diseases
 - CDC treatment guidelines for, need for revision of, 528 (letter)
 - in incarcerated women, epidemiologic study of, 531 (letter)
 - prevalence of
 - in pregnant women, in Vanuatu, 362
 - among urban Latino day laborers, 661
 - prevention of
 - Internet information sources for, 15
 - needs assessment for, in China, 600
 - in sex workers, 273
 - state policy support for, 614
 - risk factors for. *See* Risk behaviors/factors
 - screening for. *See* Screening
 - syndromic treatment of, in China, 327
 - transmission dynamics in (Thomas Parran Award Lecture), 478
 - transmission of, gap length and, 221
- Sexual mixing, spatial bridging and, in importation of gonorrhea and chlamydia, 742, 750 (editorial)
- Sexual networks, cross-border, in Hong Kong, 827
- Sexual partnerships
 - discordant
 - of high-risk adolescents, 234
 - of pregnant African American teens, 211, 214 (editorial)
 - gap length between, STD transmission and, 221
 - quantitative assessment of, 6
 - targeting meeting places for, in response to syphilis outbreak, 533
- Sex workers
 - chlamydia prevalence in, in Mexico, 195
 - drug-resistant *N. gonorrhoeae* in, in Indonesia, 178
 - enumeration of, in Madagascar, 664
 - injection drug use by, in Russia, 46
 - male, drug injection and sexual mixing patterns of, 571
 - male clients of, behavioral surveillance surveys of, in Hong Kong, 620
 - participatory mapping for, in Madagascar, 664
 - screening for gonorrhea and chlamydial infection in, in Indonesia, 671
 - social organization of, in Moscow, 39
 - sociodemographic dynamics and STDs in, at Mexican-Guatemalan border, 266
 - STD prevalence in, in Indonesia, 671
 - STD prevention in, 273
 - STD treatment algorithms for, in Côte d'Ivoire, 284
- SIS model, for assessment of intervention scenarios, 388
- Smoking, HSV-2 infection and, 405
- Soldiers
 - female, chlamydia prevalence in, 539, 545 (editorial)
 - male, HIV-infected, human herpesvirus-8 in fection in, 713
- South Africa
 - HIV-1 transmission in, migration and, 149
 - syndromic management in, role of community pharmacists in, 609
- Soviet Union, New Independent States of, sexual habits and HPV infection in females in, 680
- Spain
 - cervical HPV infection in, 788
 - N. gonorrhoeae* resistance to ciprofloxacin in, 395
 - seroprevalence among STD clinic attendees in, 876
 - urethritis in, etiologic and epidemiologic trends in, 280
- Spatial bridging, in importation of gonorrhea and chlamydia, 742, 750 (editorial)
- Specimen collection
 - of cervicovaginal secretions
 - method preferred by incarcerated women, 306
 - self-sampling methods for, 107, 306, 769, 880
 - urine, for chlamydial infection, in males, 345
- Spermicides, acceptability and product choice as indicators of use of, 556
- Students. *See* Adolescents; College students
- Substance use/abuse. *See also* Risk behaviors/factors
 - by adjudicated African American adolescents, 634
 - HIV prevalence and, in Brazil, 166
 - HIV risk and, changing perspectives on, 764
 - human herpesvirus type 8 infection and, 199
 - by male sex workers, drug injection and sexual mixing patterns of, 571
 - by sex workers, in Russia, 46 (editorial)
- Swabs
 - dry, for HPV polymerase chain reaction assay, in males, 246
 - self-collected, for cervicovaginal specimen collection, 107, 306, 769, 880
- Syndromic management
 - of bacterial vaginosis, with/without HIV-1 coinfection, 1
 - of male STDs, in China, 327
 - role of community pharmacists in
 - in Peru, 379
 - in South Africa, 609
- Syphilis
 - antibiotic prophylaxis for, 844
 - declining rates of, AIDS mortality as cause of, 419
 - incubating, azithromycin for, cost-effectiveness of, 502
 - mass treatment of, 297
 - outbreak of
 - among men who have sex with men, 872
 - targeting sex partner meeting location for, 533
 - partner notification for, effects of on sexual behaviors and relationship stability, 75, 83
 - patient characteristics with male-to-male vs. heterosexual acquisition, in Canada, 310
 - prevalence of, in pregnant women, in Vanuatu, 362
 - screening for. *See also* Screening
 - in Medicaid patients, 723
 - surveillance for, reactor grids in, 650
 - syndromic management of, in China, 327
- Syphilis reactor grids, 700

T

- Tanzania
 genital ulcer disease in, etiology and HIV coinfection in, 114
 HSV-2 infection in
 prevalence of, 187, 588
 risk factors for, 187
 Telephone hotline, in Italy, 707
 Tetracycline, *N. gonorrhoeae* resistance to, 10
 in Canada, 896
 in Cuba, 10, 443
 in India, 523
 in Indonesia, 25, 178
 in Spain, 395
 Thailand, adolescent risk behaviors in, 320
 Third world countries. *See* Developing countries
 Thomas Parran Award Lecture, 477, 478
 Topical microbicide, acceptability of to adolescent girls, 854
 Transmission dynamics (Thomas Parran Award Lecture), 478
 Treatment, syndromic. *See* Syndromic management
 Treatment adherence, HIV-transmission risk behaviors and, 399
 Treatment planning, mathematical tools for, 388
 Trichomoniasis
 in HIV infection, associated factors in, 839
 Papanicolaou test for, 694
 prevalence of, in pregnant women, in Vanuatu, 362
 treatment of
 for sex workers, in Côte d'Ivoire, 284
 in syndromic management of urethritis, in Malawi, 516

U

- Ulcers. *See* Genital ulcer disease
 Uncircumcised males, HSV-2 infection in females and, 405
Ureaplasma urealyticum urethritis, epidemiologic trends in, in Spain, 280
 Urethral discharge, syndromic management of, in China, 327
 Urethritis
 detection of HPV DNA on external genitalia of males with, 629
 gonococcal. *See* Gonorrhea/gonococcal infection
 nongonococcal
 chronic, chlamydial hsp60 antibody in, 129
 etiologic and epidemiologic trends in, in Spain, 280
 syndromic management of, trichomoniasis treatment in, in Malawi, 516

Urine testing

- for chlamydial infection
 acceptability of to adolescents, 850
 in males, 345
 for gonorrhea, acceptability of to adolescents, 850
 vs. self-collected vaginal swab
 female military recruits' preference for, 769
 incarcerated women's preference for, 306

V

Vaccination

- for hepatitis
 hepatitis A/B vs. hepatitis B vaccine for, 859
 for men who have sex with men, 411, 425, 449, 685
 among STD clinic attendees, 914
 for STDs, acceptability of among college students, 774

Vaginal discharge

- rapid diagnostic kit for, in Gambia, 483
 syndromic management of, with/without HIV-1 coinfection, 1

Vaginal douching

- early-onset, health beliefs and high-risk behavior and, 689
 HSV-2 infection and, 405
 reasons for continuing or stopping, 71

Vaginal flora

- abnormal. *See* Bacterial vaginosis
 effect of single-use *Lactobacillus crispatus* capsules on, 568

Vaginal swabs, self-collected, for cervicovaginal specimen collection, 107, 306, 769, 880

Vaginitis, treatment algorithms for, for sex workers, in Côte d'Ivoire, 284

Vaginosis. *See* Bacterial vaginosis

Valacyclovir, for genital herpes, in suppressive vs. episodic therapy, patients' preference for, 226, 232 (editorial)

Vanuatu, STD prevalence in pregnancy in, 362

W

Warts, anogenital

- 5% imiquimod cream for, 124
 frequently asked questions about, 193

Y

Young Investigator Award (ASTDA), 477

